Search Within

Adult Leukemia

Formats
  1. Meeting Abstract (1797)
  2. Journal Article (1603)
  3. Review (122)
  4. Research Letter (55)
  5. Editorial (49)
  6. Book Section (39)
  7. Guidelines (20)
  8. Conference Paper (18)
  9. Correspondence (13)
  10. Miscellaneous (3)
  11. Book Whole (1)
Groups
  1. Center for Hematologic Malignancies (3720)
  2. Department of Medicine (3689)
  3. Hematologic Malignancies, Division of (3685)
  4. GSK Faculty (1783)
  5. Center for Molecular Imaging and Biotechnology (CMIB) (1378)
  6. Executive Committee, Center for Hematologic Malignancies (970)

More Groups

People
  1. Ross Levine (787)
  2. Martin Tallman (655)
  3. David Scheinberg (502)
  4. Jae Park (387)
  5. Eytan Stein (371)
  6. Raajit Rampal (352)

More People

Years
  1. 2025 (103)
  2. 2024 (196)
  3. 2023 (233)
  4. 2022 (255)
  5. 2021 (248)
  6. 2020 (273)

More Years

Publications
  1. Blood (1254)
  2. Journal of Clinical Oncology (217)
  3. Clinical Lymphoma, Myeloma and Leukemia (117)
  4. Leukemia (110)
  5. Haematologica (107)
  6. Cancer Research (86)

More Publications

Publishers
  1. American Society of Hematology (1345)
  2. Nature Publishing Group (324)
  3. Elsevier Inc. (255)
  4. American Association for Cancer Research (234)
  5. American Society of Clinical Oncology (230)
  6. Ferrata Storti Foundation (107)

More Publishers

Results (3720)


Citation style sort is year ascending, and then by author or title. Author ascending is default.
  • Addition of crenolanib to induction chemotherapy overcomes the poor prognostic impact of co-occurring driver mutations in patients with newly diagnosed FLT3-mutated AML
    Meeting Abstract

    Goldberg, A. D.; Collins, R. H.; Stone, R. M.; Walter, R. B.; Karanes, C.; Vigil, C. E.; Wang, E. S.; Tallman, M. S.
    Blood (2018)

    Fulltext@MSK | Save
  • Molecular predictors and current management of minimal residual disease (MRD) following induction chemotherapy for acute myeloid leukemia (AML)
    Meeting Abstract

    Goldberg, A. D.; Famulare, C.; Devlin, S. M.; Farnoud, N.; Menghrajani, K.; Patel, M.; Cai, S.; Dunbar, A.; Epstein-Peterson, Z. D.; McGovern, E.; more...
    Blood (2018)

    Fulltext@MSK | Save
  • Prediction of CAR T-related toxicities in R/R DLBCL patients treated with axicabtagene ciloleucel using point of care cytokine measurements
    Meeting Abstract

    Faramand, R.; Kotani, H.; Morrissey, D.; Yu, B.; Locke, F. L.; Jain, M. D.; Chavez, J. C.; Wang, X.; Mishra, A.; Bachmeier, C. A.; more...
    Blood (2018)

    Fulltext@MSK | Save
  • Minimal residual disease (MRD) at time of complete remission is commonly detected in acute myeloid leukemia (AML) patients age ≥ 60 years and significantly impacts outcome based on post-remission treatment strategies: Prospective analysis of ECOG-ACRIN (E-A) E2906 phase III trial
    Meeting Abstract

    Foran, J. M.; Sun, Z.; Paietta, E.; Racevskis, J.; Claxton, D. F.; Lazarus, H. M.; Arber, D. A.; Rowe, J. M.; Altman, J. K.; Al-Kali, A.; more...
    Blood (2018)

    Fulltext@MSK | Save
  • Ivosidenib (AG-120) induced durable remissions and transfusion independence in patients with IDH1-mutant relapsed or refractory myelodysplastic syndrome: Results from a phase 1 dose escalation and expansion study
    Meeting Abstract

    DiNardo, C. D.; Watts, J. M.; Stein, E. M.; de Botton, S.; Fathi, A. T.; Prince, G. T.; Stein, A. S.; Foran, J. M.; Stone, R. M.; Patel, P. A.; more...
    Blood (2018)

    Fulltext@MSK | Save
  • Early results from a biomarker-directed phase 2 trial of SY-1425 in combination with azacitidine or daratumumab in non-APL acute myeloid leukemia (AML) and myelodysplastic syndrome (MDS)
    Meeting Abstract

    Cook, R. J.; Moyo, T.; Liesveld, J. L.; Rizzieri, D. A.; Stein, E. M.; De Botton, S.; Roboz, G. J.; Sekeres, M. A.; Jurcic, J. G.; Raza, A.; more...
    Blood (2018)

    Fulltext@MSK | Save
  • Dosing patterns of dasatinib use in simplicity, an observational study in chronic phase chronic myeloid leukemia (CP-CML) patients (pts) in routine clinical practice
    Meeting Abstract

    Cortes, J. E.; Chen, C.; Mauro, M. J.; Sen, G. P.; Gajavelli, S.; Davis, C.; Goldberg, S. L.
    Blood (2018)

    Fulltext@MSK | Save
  • Genomic and proteomic profiling of AF10-fusion oncoproteins reveal mechanisms of leukemogenesis and actionable targets
    Meeting Abstract

    Chen, B. R.; Deshpande, A.; Kleppe, M.; Yeddula, N.; Yoh, S.; Armstrong, S. A.; Levine, R. L.; Chanda, S.; Deshpande, A. J.
    Blood (2018)

    Fulltext@MSK | Save
  • Initial report of the beat AML umbrella study for previously untreated AML: Evidence of feasibility and early success in molecularly driven phase 1 and 2 studies
    Meeting Abstract

    Burd, A.; Levine, R. L.; Shoben, A.; Mims, A. S.; Borate, U.; Stein, E. M.; Patel, P. A.; Baer, M. R.; Stock, W.; Deininger, M. W.; more...
    Blood (2018)

    Fulltext@MSK | Save
  • A phase 2 study of actinium-225 ((225)Ac)-lintuzumab in older patients with untreated acute myeloid leukemia (AML) - Interim analysis of 1.5 µci/kg/dose
    Meeting Abstract

    Atallah, E. L.; Orozco, J. J.; Craig, M.; Levy, M. Y.; Finn, L. E.; Khan, S. S.; Perl, A. E.; Park, J. H.; Roboz, G. J.; Tse, W.; more...
    Blood (2018)

    Fulltext@MSK | Save